Advanced techniques optimize antibody drug development. Biointron shows how CHO cells and process innovations improve yields, stability, and therapeutic outcomes.
CHO cells are the gold standard for antibody production. Biointron applies codon optimization, advanced vectors, and stable expression systems to deliver high-yield recombinant antibodies.
Examine how CHO cell line development and optimized upstream processing improve therapeutic antibody production, ensuring high yields, consistent quality, and clinical efficacy.
Discover how hybridoma sequencing prevents cell line loss, ensures accurate antibody sequences, and enables recombinant expression for consistent, scalable antibody production.
You can also contact us on the Scientist and Science Exchange marketplaces.
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.
Biointron uses cookies and similar technologies to ensure proper website functionality, understand how visitors use our website, and improve our content and services. Necessary cookies are enabled by default.
By clicking “Accept All”, you agree to the use of all cookies, including analytics and optional cookies that help us understand website usage and improve user experience. By clicking “Reject Non-Essential”, only necessary cookies will be used.
You may manage or change your cookie preferences at any time by clicking “Cookie Settings” at the bottom of the website.
For more information about how we use cookies and process personal data, please review our Privacy Policy.
